Rexulti (brexpiprazole) is a brand-name drug prescribed for certain mental health conditions. Rexulti comes as an oral tablet that’s typically taken once per day. The dosage can vary depending on what ...

Rexulti, a brexpiprazole oral tablet, has a recommended starting dosage of 0.5 mg once daily for seven days, which increases steadily to 2 milligrams after 15 days, according to a May 10 agency news ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the ...

WASHINGTON (TND) — A medication has been approved to treat symptoms of dementia, theU.S. Food and Drug Administration (FDA) announced Thursday. The agency said Rexulti, an oral tablet, marks thefirst ...

For the first time, the Food and Drug Administration has approved a drug to treat agitation related to Alzheimer’s disease dementia. Patient advocates are hailing the news, but prescribing the drug, ...

Please provide your email address to receive an email when new articles are posted on . Approval makes Rexulti the lone treatment approved for agitation associated with Alzheimer’s dementia. Two FDA ...

The Food and Drug Administration has given Otsuka and Lundbeck approval for Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer's disease.

(RTTNews) - The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Brexpiprazole tablets are indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder and for the treatment of schizophrenia. Alembic has received the Food and ...

On its May 10 PDUFA date, the U.S. FDA approved serotonin-dopamine modulator Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. and H. Lundbeck A/S for agitation in Alzheimer’s disease ...